Verapamil Hydrochloride Injection
Function and Efficacy
1. Verapamil hydrochloride is a calcium ion antagonist. It exerts its pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, but does not change the serum calcium concentration. 2. Verapamil hydrochloride dilates the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonizes spontaneous or ergonovine-induced coronary artery spasm, increases the delivery of myocardial oxygen to the heart of patients with coronary artery spasm, relieves and prevents coronary artery spasm; verapamil reduces total peripheral resistance and reduces myocardial oxygen consumption. It can be used to treat variant angina and unstable angina. 3. Verapamil reduces the influx of calcium ions, prolongs the effective refractory period of the atrioventricular node, slows conduction, and can reduce
Ingredients
The main ingredient and chemical name of this product are: α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-isopropylphenylacetonitrile hydrochloride
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| (+/-)-Verapamil hydrochlorideIngredients |
Calcium ion antagonists exert their pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells; they dilate the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase myocardial oxygen delivery in patients with coronary artery spasm, relieve and prevent coronary artery spasm; they reduce total peripheral resistance and myocardial oxygen consumption; they reduce the influx of calcium ions, prolong the effective refractory period of the atrioventricular node, and slow down conduction. More |
152-11-4 | 13 |
Appearance
This product is a colorless clear liquid.
Indication
1. Cardioversion of rapid paroxysmal supraventricular tachycardia. Vagus nerve inhibition (such as Valsalva method) should be the first choice before applying verapamil. 2. Temporary control of ventricular rate in atrial flutter or atrial fibrillation. Except when atrial flutter or atrial fibrillation is combined with atrioventricular bypass pathway (preexcitation syndrome and LGL syndrome).
Usage and Dosage
It must be injected slowly intravenously for at least 2 minutes under continuous ECG monitoring and blood pressure monitoring. This injection has no incompatibility with Ringer's solution, 5% glucose injection or sodium chloride injection. Because the optimal dosing interval for repeated intravenous administration cannot be determined, individualized treatment is required. The general starting dose is 5-10 mg (or 0.075-0.15 mg/Kg body weight), which is slowly injected intravenously for at least 2 minutes after dilution. If the initial reaction is not satisfactory, give another 5-10 mg or 0.15 mg/Kg body weight 15-30 minutes after the first dose. Intravenous drip administration, 5-10 mg per hour, added to sodium chloride injection or 5% glucose injection and dripped intravenously, the total amount per day should not exceed 50-100 mg.
Adverse Reactions
Take the recommended single dose and total daily dose as the starting dose and gradually adjust the dose upward. Serious adverse reactions are rare. Adverse reactions with an incidence of 1-10%: constipation (7.3%); dizziness, mild headache (3.5%); nausea (2.7%); hypotension (2.5%); headache (2.2%). Peripheral edema (2.1%); congestive heart failure (1.8%); sinus bradycardia, I, II or III degree atrioventricular block; rash (1.2%); fatigue; palpitations; increased transaminases, with or without increased alkaline phosphatase and bilirubin, which are sometimes transient and may disappear even with continued use of verapamil. Adverse reactions with an incidence of <1%: hypotension; tachycardia; flushing; galactorrhea; gingival hyperplasia; non-obstructive paralytic intestinal infarction
Precautions
1 Severe left ventricular dysfunction. 2 Hypotension (systolic blood pressure less than 90 mmHg) or cardiogenic shock. 3 Sick sinus syndrome (except patients with a pacemaker installed and functioning). 4 II or III degree atrioventricular block (except patients with a pacemaker installed and functioning). 5 Patients with atrial flutter or atrial fibrillation combined with atrioventricular bypass pathway. 6 Patients known to be allergic to verapamil hydrochloride.
Drug Interactions
1 Cytotoxic drugs such as cyclophosphamide, vincristine, procarbazine, prednisone, vinblastine, doxorubicin, and cisplatin reduce the absorption of verapamil. 2 Phenobarbital, hydantoin, vitamin D, sulfamethoxazole, and ramifluan reduce the plasma concentration of verapamil by increasing liver metabolism. 3 Cimetidine may increase the bioavailability of verapamil. 4 Verapamil inhibits the elimination of ethanol, leading to increased ethanol concentration in the blood, which may prolong the toxic effects of alcohol. 5 A few cases reported that the combined use of verapamil and aspirin prolonged bleeding time compared with aspirin alone. 6 Combined with beta-blockers
Storage
Keep in a light-proof and airtight container.
Packaging Specification
2ml:5mg
Manufacturer
JiangSu Ruinian Qianjin Pharmaceutical Co., Ltd.
-
Founded in:
1979-11-20 -
Address:
Chuanbu Village, Dingshu Town, Yixing City -
Tax NO.:
91320282142846159Q -
Registered Funds:
31 million yuan -
Email: